Seratrodast
(Synonyms: 塞曲司特; AA 2414) 目录号 : GC18111
A thromboxane A2 receptor antagonist
Cas No.:112665-43-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
IC50: 7.4 nM for guinea pig platelets
Seratrodast is a thromboxane A2 (TXA2) receptor antagonist.
Thromboxane A2, a type of thromboxane, is produced by activated platelets and has prothrombotic properties, such as stimulating activation of new platelets and increasing platelet aggregation.
In vitro: Seratrodast was found to inhibit the aggregation of guinea pig platelets induced by a prostaglandin endoperoxide analogue, U-44069 and the specific binding of another analogue, [3H]U-46619 to washed guinea pig platelets. Seratrodast could competitively inhibit the contraction of rabbit aorta and pig coronary arteries induced by U-44069. Seratrodast also inhibited the contraction of rabbit aorta induced by PGF2 alpha and the contraction of pig coronary arteries. However, seratrodast had no effect on the antiaggregatory effect of guinea pig platelets [1].
In vivo: In experiments with guinea pigs, oral seratrodast at 0.1-1 mg/kg could dose-dependently inhibit the platelet aggregation induced by U-44069; the inhibition at 1 mg/kg was 100% at 1 hr and was 89% even at 24 hr after seratrodast administration [1].
Clinical trial: So far, no clinical study has been conducted.
Reference:
[1] Imura, Y. ,Terashita, Z.,Shibouta, Y., et al. Antagonistic action of AA-2414 on thromboxane A2/prostaglandin endoperoxide receptor in platelets and blood vessels. Japanese Journal of Pharmacology 52(1), 35-53 (1990).
| Cas No. | 112665-43-7 | SDF | |
| 别名 | 塞曲司特; AA 2414 | ||
| 化学名 | ζ-(2,4,5-trimethyl-3,6-dioxo-1,4-cyclohexadien-1-yl)-benzeneheptanoic acid | ||
| Canonical SMILES | OC(CCCCCC(C1=CC=CC=C1)C(C(C(C)=C2C)=O)=C(C)C2=O)=O | ||
| 分子式 | C22H26O4 | 分子量 | 354.4 |
| 溶解度 | ≥ 10.9mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.8217 mL | 14.1084 mL | 28.2167 mL |
| 5 mM | 0.5643 mL | 2.8217 mL | 5.6433 mL |
| 10 mM | 0.2822 mL | 1.4108 mL | 2.8217 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。